iShares US Aerospace & Defense ETF vs Zoetis Inc — how do they compare? iShares US Aerospace & Defense ETF trades at $206.65 (market cap $11.87B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.5× iShares US Aerospace & Defense ETF's market cap, and Zoetis Inc pays a 2.9% dividend while iShares US Aerospace & Defense ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Aerospace & Defense ETF for 19 Days and Zoetis Inc for 70 Days on average.
| ITA | ZTS | |
|---|---|---|
Market Cap | $11.87B | $30.20B |
Volume | 1,060,125 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $253.22 | $147.53 |
52-Week Low | $198.23 | $69.09 |
Typical Hold Time | 19 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Trailing returns across standard periods
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →